Anshika Panday
Identifying and validating suitable drug targets are a critical step in the process of therapeutic development. This abstract discusses the advances in the field of exploring drug targets, focusing on the identification and validation strategies that have revolutionized the discovery of novel therapeutic targets. The abstract begins by highlighting the importance of identifying and targeting specific molecules or pathways that play a crucial role in disease progression. Traditional drug discovery approaches often relied on serendipitous discoveries or targeting well-known protein families. However, recent advancements in molecular biology, genomics, and bioinformatics have enabled more systematic and targeted approaches for identifying potential drug targets. The abstract discusses the application of high-throughput screening techniques, such as chemical libraries, RNA interference (RNAi), and CRISPR-Cas9 gene editing, in the identification of drug targets. These approaches allow for the screening of large numbers of molecules or genes to identify those that modulate disease-relevant phenotypes or pathways. The integration of computational modeling and data analysis has further enhanced the efficiency and accuracy of target identification, facilitating the discovery of novel targets with therapeutic potential. Validation of drug targets is another crucial aspect of the drug discovery process. The abstract highlights the importance of employing multiple validation strategies to ensure the specificity, efficacy, and safety of potential targets. These strategies include in vitro and in vivo assays, animal models, and patient-derived samples. The use of advanced imaging techniques, such as positron emission tomography (PET) and magnetic resonance imaging (MRI), has enabled non-invasive evaluation of target engagement and therapeutic response in preclinical and clinical settings. Furthermore, the abstract discusses the emergence of omics technologies, such as genomics, proteomics, and metabolomics, in the identification and validation of drug targets. These technologies provide a comprehensive understanding of disease mechanisms, biomarker identification, and patient stratification, leading to the discovery of targets that are tailored to specific disease subtypes or patient populations. The abstract also highlights the significance of target druggability assessment, which involves evaluating the feasibility of modulating the target with small molecules or biologics. This assessment considers factors such as target accessibility, binding sites, and the presence of known ligands or inhibitors. In conclusion, the exploration of drug targets has been revolutionized by advances in identification and validation strategies. High-throughput screening, computational modeling, omics technologies, and target druggability assessment have accelerated the discovery of novel therapeutic targets. Integration of these approaches with traditional validation techniques and imaging technologies enhances the precision and confidence in target selection. This abstract underscores the importance of a comprehensive and systematic approach in identifying and validating drug targets for successful therapeutic development and the potential to transform patient care in various disease areas.
KeywordsBioinformatics; Computational modeling; Omics technologies; Target druggability
English 
Spanish 
Chinese 
Russian 
French 
Japanese 
Portuguese 
Hindi